Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVaidya, Binit-
dc.contributor.authorAdhikari, Bhojraj-
dc.contributor.authorBhochhibhoya, Manisha-
dc.contributor.authorNakarmi, Shweta-
dc.identifier.citationVaidyaB., AdhikariB., BhochhibhoyaM., & NakarmiS. (2021). Late Onset Dipeptidyl Peptidase -4 Inhibitor Associated Seronegative Rheumatoid Arthritis. Journal of Nepal Health Research Council, 19(03), 644-646.
dc.identifier.issnPrint ISSN: 1727-5482; Online ISSN: 1999-6217-
dc.descriptionCase Reporten_US
dc.description.abstractAbstract Drug-induced arthritis is not an uncommon scenario. DPP-4 inhibitors could potentially cause adverse-events mediated by cytokine-induced inflammation leading to arthritis. The activity of the DPP-4 enzyme could be inversely related to the development of rheumatoid arthritis, explaining the increased inflammatory activity with its inhibition by a drug. We discuss a 72-year-old gentleman with twenty-three years of history of type 2 diabetes mellitus, who after 6 years of treatment with a DPP-4 inhibitor, developed features of inflammatory arthritis and fulfilled the criteria for seronegative rheumatoid; which eventually subsided after stopping the drug. Keywords: DDP-4 inhibitor; diabetes mellitus; Nepal; rheumatoid arthritis; seronegativeen_US
dc.publisherNepal Health Research Councilen_US
dc.relation.ispartofseriesJuly-Sep, 2021;3433-
dc.subjectDDP-4 inhibitoren_US
dc.subjectdiabetes mellitusen_US
dc.subjectrheumatoid arthritisen_US
dc.titleLate Onset Dipeptidyl Peptidase -4 Inhibitor Associated Seronegative Rheumatoid Arthritisen_US
dc.typeJournal Articleen_US
local.journal.categoryCase Report-
Appears in Collections:Vol. 19 No. 03 (2021): Vol 19 No 3 Issue 52 Jul-Sep 2021

Files in This Item:
File Description SizeFormat 
3433-Manuscript-25092-1-10-20211215.pdfFulltext Download412.78 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.